Vontobel Holding Ltd. Invests $377,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Vontobel Holding Ltd. purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 7,895 shares of the biopharmaceutical company's stock, valued at approximately $377,000.

Several other institutional investors and hedge funds also recently made changes to their positions in HALO. Geode Capital Management LLC grew its stake in Halozyme Therapeutics by 1.0% in the third quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company's stock valued at $175,194,000 after acquiring an additional 30,901 shares during the period. Congress Asset Management Co. lifted its holdings in shares of Halozyme Therapeutics by 446.5% in the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company's stock valued at $139,298,000 after purchasing an additional 1,988,238 shares in the last quarter. Boston Trust Walden Corp lifted its holdings in shares of Halozyme Therapeutics by 28.0% in the fourth quarter. Boston Trust Walden Corp now owns 874,081 shares of the biopharmaceutical company's stock valued at $41,790,000 after purchasing an additional 191,465 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Halozyme Therapeutics by 6.2% in the third quarter. Janus Henderson Group PLC now owns 545,173 shares of the biopharmaceutical company's stock valued at $31,204,000 after purchasing an additional 31,871 shares in the last quarter. Finally, Glenmede Trust Co. NA lifted its holdings in Halozyme Therapeutics by 28.9% during the third quarter. Glenmede Trust Co. NA now owns 487,131 shares of the biopharmaceutical company's stock worth $27,883,000 after acquiring an additional 109,283 shares during the period. Institutional investors and hedge funds own 97.79% of the company's stock.

Wall Street Analyst Weigh In

HALO has been the subject of several recent research reports. Wells Fargo & Company reduced their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. JMP Securities upped their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a research report on Friday, November 1st. HC Wainwright increased their price target on Halozyme Therapeutics from $70.00 to $72.00 and gave the company a "buy" rating in a report on Wednesday. Piper Sandler increased their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research note on Friday, January 10th. Finally, Benchmark reissued a "buy" rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Halozyme Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $62.78.

Insider Activity

In other news, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the sale, the director now owns 38,611 shares in the company, valued at $2,173,799.30. This represents a 11.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 2.40% of the company's stock.

Halozyme Therapeutics Price Performance

Shares of HALO stock traded up $0.31 during mid-day trading on Friday, reaching $57.75. The stock had a trading volume of 1,299,523 shares, compared to its average volume of 1,313,186. The company has a market cap of $7.11 billion, a P/E ratio of 16.84, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25. The business has a 50-day simple moving average of $53.46 and a 200 day simple moving average of $54.62. Halozyme Therapeutics, Inc. has a 12-month low of $37.73 and a 12-month high of $65.53. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.02. The business had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. On average, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.72 earnings per share for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.